ExL’s 3rd Quality Oversight of Clinical Vendors Conference, taking place October 22-24 at the Westin Alexandria, provides risk-based strategies for assessing and managing quality at CROs and other clinical providers. Attracting a loyal audience of both senior-level clinical quality and clinical operations executives from mostly pharma, biotech and medical device companies, this unique event offers a highly interactive forum where participants candidly share both positive and negative experiences resulting in an honest and educational exchange of lessons learned and best practices.
Esther Timmeney, Compliance Advice and Assurance Advisor, AstraZeneca
"The conference and speakers were all excellent. This was a very valuable conference and input from the participants will improve our quality oversight of vendors."
Brandy Schenck, Auditor, Quality Assurance, Infinity Pharmaceuticals
"This was one of the best I’ve attended in a long while. Interactions were excellent."
Grace Crawford, Senior Director, QA, ICON
"Excellent. Well worth the time attending. Great representation from industry for speakers—not the same old crowd."
Linda Donahoe, Director, Genzyme
"Conference was a positive open forum that provided an opportunity for sponsors and vendors to come together and share experiences, lessons learned, and identify a path to improve sponsor oversight through better channels of communication."
Maryann Livolsi, Associate Director, Global R&D Quality Assurance, Shire Pharmaceuticals
"Exceeded expectations. Excellent conference with excellent speakers. All of us learned a lot and conferences like these are what improve the drug development process.."
Munish Mehra, PhD, Managing Director, Global Drug Development Experts
"This seminar was one of the best I have attended."
Joan Millsaps,Director, Business Operations & Outsourcing Management, Bristol-Myers Squibb Corporation
Audience Profile from 2011 Event
This event is designed for C-Level, Vice President, Director & Manager level executives from the following departments at Pharma/Biotech/Medical Device companies, CROs and other clinical trial service providers: